Granted Patent B2

US 12,297,208 · App. 18/311,639 · Granted May 13, 2025

Inventors: Indu Bharathan (Somerville, MA); Symon Gathiaka (Waltham, MA); Yongxin Han (Needham, MA); Xiaoshen Ma (Boston, MA); Ryan D. Otte (Natick, MA); David L. Sloman (Newton, MA); Thomas H. Graham (Somerville, MA); Timothy Henderson (Natick, MA); Elisabeth Hennessy (Weston, MA); Anandan Palani (Needham, MA)

Assignee: Merck Sharp & Dohme LLC

C07D498/22A61K31/519A61P35/00C07D471/22C07D519/00C07B2200/05

Abstract

Claims (18)

1. A method of treating cancer comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, wherein the compound is selected from the group consisting of:

2. The method of claim 1 , further comprising administering an additional active agent to the subject, wherein the additional active agent is an anti-cancer agent.

3. The method of claim 2 , wherein the anti-cancer agent is selected from an EGFR inhibitor, an anti-PD-1 agent, a SHP2 inhibitor, and an ERK inhibitor.

4. The method of claim 3 , wherein the anti-cancer agent is an EGFR inhibitor.

5. The method of claim 3 , wherein the anti-cancer agent is an anti-PD-1 agent.

6. The method of claim 5 , wherein the anti-PD-1 agent is pembrolizumab.

7. The method of claim 3 , wherein the anti-cancer agent is a SHP2 inhibitor.

8. The method of claim 3 , wherein the anti-cancer agent is an ERK inhibitor.

9. The method of claim 1 , wherein the cancer is selected from pancreatic cancer, colorectal cancer, and lung cancer.

10. The method of claim 3 , wherein the cancer is selected from pancreatic cancer, colorectal cancer, and lung cancer.

11. The method of claim 1 , wherein the cancer is mediated by a KRAS G12C mutation.

12. The method of claim 1 , wherein the subject is a human.

13. The method of claim 12 , wherein the compound or the pharmaceutically acceptable salt thereof is administered orally.

14. A method of treating cancer comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, wherein the compound is:

15. A method of treating cancer comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, wherein the compound is:

16. A method of treating cancer comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, wherein the compound is:

17. A method of treating cancer comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, wherein the compound is:

18. A method of treating cancer comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, wherein the compound is:

Assignments (2)

Continuity (4)

References Cited (256)